The loss of MMS22L, or its binding partner TONSL, which work together to facilitate RAD51 deposition in HR, were shown to sensitize PCa cell lines to PARP inhibitors [117,118,119]. The gene discussed is PARP1; the disease is posterior cortical atrophy.